Optimal Timing of Zoster Vaccination After Shingles: A Prospective Study of the Immunogenicity and Safety of Live Zoster Vaccine
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Zoster vaccination is recommended for people with a history of herpes zoster (HZ), but the most effective timing of vaccine administration after zoster illness is unresolved. This prospective observational study compared the immunogenicity and safety of administering HZ vaccine at 6-12 months and 1-5 years after zoster illness. Materials and Methods: Blood samples were collected before the administration of live zoster vaccine and 6 weeks after vaccination. Varicella-zoster virus (VZV) IgG concentrations and T-cell responses were assessed by glycoprotein enzyme-linked immunosorbent assay and interferon-γ enzyme-linked immunospot assay (ELISPOT), respectively. Results: The baseline geometric mean value (GMV) of VZV IgG was higher in the 6-12 months group than in the 1-5 years group (245.5 IU/mL vs. 125.9 IU/mL; P = 0.021). However, the GMV increased significantly in both groups (P = 0.002 in the 6-12 months group; P <0.001 in the 1-5 years group). The results of the ELISPOT assay were not significant for differences of the GMV between baseline and 6-week post-vaccination groups, while the GMV increased significantly in both groups (P = 0.001 in the 6-12 months group; P <0.001 in the 1-5 years group). Conclusion: The immunogenicity of zoster vaccine may be similar whether administered 6-12 months, or >1 year after zoster illness. Trial Registration: ClinicalTrials.gov Identifier: NCT02704572
Abstract
Background: Zoster vaccination is recommended for people with a history of herpes zoster (HZ), but the most effective timing of vaccine administration after zoster illness is unresolved. This prospective observational study compared the immunogenicity and safety of administering HZ vaccine at 6-12 months and 1-5 years after zoster illness. Materials and Methods: Blood samples were collected before the administration of live zoster vaccine and 6 weeks after vaccination. Varicella-zoster virus (VZV) IgG concentrations and T-cell responses were assessed by glycoprotein enzyme-linked immunosorbent assay and interferon-γ enzyme-linked immunospot assay (ELISPOT), respectively. Results: The baseline geometric mean value (GMV) of VZV IgG was higher in the 6-12 months group than in the 1-5 years group (245.5 IU/mL vs. 125.9 IU/mL; P = 0.021). However, the GMV increased significantly in both groups (P = 0.002 in the 6-12 months group; P <0.001 in the 1-5 years group). The results of the ELISPOT assay were not significant for differences of the GMV between baseline and 6-week post-vaccination groups, while the GMV increased significantly in both groups (P = 0.001 in the 6-12 months group; P <0.001 in the 1-5 years group). Conclusion: The immunogenicity of zoster vaccine may be similar whether administered 6-12 months, or >1 year after zoster illness. Trial Registration: ClinicalTrials.gov Identifier: NCT02704572
참고문헌 (21)
- Bowsher D, "The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population", Eur J Pain, 3, pp.335~342 (1999)
- van Hoek AJ, "Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales", Vaccine, 27, pp.1454~1467 (2009)
- Schmader K, "The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine", J Infect Dis, 197(Suppl 2), pp.S207~S215 (2008)
- Cohen JI, "Clinical practice: Herpes zoster", N Engl J Med, 369, pp.255~263 (2013)
- Yawn BP, "Herpes zoster recurrences more frequent than previously reported", Mayo Clin Proc, 86, pp.88~93 (2011)
- Dooling KL, "Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines", MMWR Morb Mortal Wkly Rep, 67, pp.103~108 (2018)
- Mills R, "Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster", Vaccine, 28, pp.4204~4209 (2010)
- Tseng HF, "Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population", J Infect Dis, 206, pp.190~196 (2012)
- "The Australian immunisation handbook"[URL]
- "Update on the Use of Herpes Zoster Vaccine"[URL]
- "Vaccination against shingles: 2015/16, Information for healthcare professionals"[URL]
- Kim JW, "Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy", J Clin Virol, 73, pp.64~69 (2015)
- Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials, "Food and Drug Administration", Botswana Government, ~ (2007)
- Oxman MN, "Immunization to reduce the frequency and severity of herpes zoster and its complications", Neurology, 45(12 Suppl 8), pp.S41~S46 (1995)
- Levin MJ, "Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine", J Infect Dis, 197, pp.825~835 (2008)
- Weinberg A, "Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine", J Infect Dis, 200, pp.1068~1077 (2009)
- Gilbert PB, "Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve", J Infect Dis, 210, pp.1573~1581 (2014)
- Levin MJ, "Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults", J Infect Dis, 213, pp.14~22 (2016)
- Helgason S, "The clinical course of herpes zoster: a prospective study in primary care", Eur J Gen Pract, 2, pp.12~16 (1996)
- Donahue JG, "The incidence of herpes zoster", Arch Intern Med, 155, pp.1605~1609 (1995)
- Ragozzino MW, "Population-based study of herpes zoster and its sequelae", Medicine, 61, pp.310~316 (1982)